3 days Ago By ABMN Staff
Crinetics Pharmaceuticals, Inc. ( NASDAQ:CRNX – Free Report ) – Research analysts at Cantor Fitzgerald raised their FY2024 earnings per share (EPS) estimates for Crinetics Pharmaceuticals in a research report issued on Wednesday, November 13th. Cantor Fitzgerald analyst J.
Schimmer now anticipates that the company will earn ($3.69) per share for the year, up from their prior forecast of ($3.91).
Cantor Fitzgerald has a “Overweight” rating and a $90.00 price target on the stock. The consensus estimate for Crinetics Pharmaceuticals’ current full-year earnings is ($3.
75) per share. CRNX has been the subject of a number of other research reports. Oppenheimer reaffirmed an “outperform” rating and set a $73.
00 price target (down previously from $74.00) on shares of Crinetics Pharmaceuticals in a report on Friday, August 9th. JMP Securities restated a “market outperform” rating and set a $80.
00 target price on shares of Crinetics Pharmaceuticals in a research note on Friday, September 27th. HC Wainwright lifted their price target on Crinetics Pharmaceuticals from $69.00 to $81.
00 and gave the company a “buy” rating in a research note on Wednesday, November 13th. Finally, Citigroup upped their price objective on Crinetics Pharmaceuticals from $70.00 to $74.
00 and gave the stock a “buy” rating in a research report on Thursday, November 14th. One research analyst has rated the stock with a hold rating and ten have assigned a buy rating to the stock. According to data from MarketBeat.
com, the company has a consensus rating of “Moderate Buy” and an average price target of $70.18. Crinetics Pharmaceuticals Stock Down 1.
9 % Shares of Crinetics Pharmaceuticals stock opened at $53.70 on Monday. Crinetics Pharmaceuticals has a 12-month low of $29.
23 and a 12-month high of $62.53. The company has a market capitalization of $4.
98 billion, a price-to-earnings ratio of -14.40 and a beta of 0.62.
The firm’s 50-day moving average price is $55.00 and its two-hundred day moving average price is $51.37.
Crinetics Pharmaceuticals ( NASDAQ:CRNX – Get Free Report ) last released its earnings results on Tuesday, November 12th. The company reported ($0.96) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.
91) by ($0.05). During the same period in the prior year, the business earned ($1.
01) earnings per share. Institutional Inflows and Outflows Large investors have recently bought and sold shares of the stock. Driehaus Capital Management LLC grew its position in shares of Crinetics Pharmaceuticals by 17.
0% in the 2nd quarter. Driehaus Capital Management LLC now owns 6,112,173 shares of the company’s stock valued at $273,764,000 after buying an additional 885,876 shares during the last quarter. FMR LLC lifted its stake in shares of Crinetics Pharmaceuticals by 8.
8% in the third quarter. FMR LLC now owns 4,455,770 shares of the company’s stock worth $227,690,000 after acquiring an additional 358,975 shares during the period. Price T Rowe Associates Inc.
MD boosted its holdings in Crinetics Pharmaceuticals by 27.1% in the first quarter. Price T Rowe Associates Inc.
MD now owns 3,823,218 shares of the company’s stock valued at $178,966,000 after acquiring an additional 814,360 shares during the last quarter. Vanguard Group Inc. boosted its holdings in Crinetics Pharmaceuticals by 2.
1% in the first quarter. Vanguard Group Inc. now owns 3,575,076 shares of the company’s stock valued at $167,349,000 after acquiring an additional 72,624 shares during the last quarter.
Finally, State Street Corp increased its position in Crinetics Pharmaceuticals by 0.9% during the 3rd quarter. State Street Corp now owns 2,838,484 shares of the company’s stock valued at $145,047,000 after purchasing an additional 25,561 shares during the period.
98.51% of the stock is owned by institutional investors. Insiders Place Their Bets In other news, insider Dana Pizzuti sold 14,375 shares of Crinetics Pharmaceuticals stock in a transaction on Thursday, October 3rd.
The shares were sold at an average price of $54.63, for a total transaction of $785,306.25.
Following the transaction, the insider now owns 28,507 shares in the company, valued at approximately $1,557,337.41. The trade was a 33.
52 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website . Also, CFO Marc Wilson sold 25,000 shares of the business’s stock in a transaction on Thursday, September 26th.
The stock was sold at an average price of $51.11, for a total transaction of $1,277,750.00.
Following the completion of the sale, the chief financial officer now directly owns 111,092 shares in the company, valued at approximately $5,677,912.12. This represents a 18.
37 % decrease in their position. The disclosure for this sale can be found here . Insiders sold a total of 43,410 shares of company stock valued at $2,275,929 in the last 90 days.
Corporate insiders own 6.00% of the company’s stock. Crinetics Pharmaceuticals Company Profile ( Get Free Report ) Crinetics Pharmaceuticals, Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors.
The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. Recommended Stories Receive News & Ratings for Crinetics Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crinetics Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter .
.
